UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

 

UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
E

ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Results, Dasatinib + Blina Induction for Older Ph+, Best TKI to Use in Frontline Setting

By UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review FEATURING Eunice Wang
By UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review FEATURING Eunice Wang
0 views
March 9, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Hematology Highlights: A Post ASH Review
15:04
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

New Therapies in AML: Is It Safe to Wait for Genomic Info to Start T…

Feat. E. Wang
13:32
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

AML Treatment Options: Modulating p53 Pathways, Targeting FLT3 Inhib…

Feat. E. Wang
10:46
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Harnessing the Immune System - Immunotherapy for AML, Targeting Anti…

Feat. E. Wang
18:28
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Malignancy-Associated Thrombosis: DOACs in Treatment of Cancer-Assoc…

Feat. B. McMahon
14:19
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombos…

Feat. B. McMahon
10:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide…

Feat. N. Fowler
11:25
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Updates in Aggressive NHL: Liso-cel in R/R DLBCL, CD19 Loss…

Feat. N. Fowler
08:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CAR T-cell for MCL, LOXO-305 Effective in Pretreated B-Cell, Nivo an…

Feat. N. Fowler
11:56
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VM…

Feat. A. Rosko
09:20
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Curative Strategy for High-Risk Smoldering Myeloma, Consolidation Th…

Feat. A. Rosko
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Respons…

Feat. A. Rosko
17:27
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CLL Therapy in 2020 - Ibrutinib+ Rituximab Provides Superior PFS and…

Feat. R. Bociek
15:39
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

CLL Highlights from ASH: Chemo Free Therapy Achieves MRD Clearance, …

Feat. R. Bociek
09:52
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Impact of Next Generation Sequencing on MDS, Scoring System & Cl…

Feat. H. Carraway
17:41
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Treatment of 62 y/o Man With Low Risk MDS With Anemia: Data on Lenal…

Feat. H. Carraway
13:11
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Emerging Therapies in MDS: Novel Oral HMT May Become Basis of New Ba…

Feat. H. Carraway
13:21
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 AML Update: Is It Safe to Wait for Genomic Info to Start Th…

Feat. E. Wang
12:03
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 AML Update: Ven-based Therapy Can Provide a Path to AlloSCT…

Feat. E. Wang
08:48
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 ALL Update: Reduced-intensity Chemo Shows Encouraging Resul…

Feat. E. Wang
13:02
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

Current Treatment Algorithm & Disease Complications in ET, PV, M…

Feat. A. Tefferi
17:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Update in MPN: Triple Negative ET, Ropeginterferon in PV &a…

Feat. A. Tefferi